A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain, on Mar 8, 2024. LONDON: Patients with type 2 diabetes taking GLP-1 treatments, which include Ozempic, have a lower chance of developing 10 types of obesity-related cancers than those taking insulin and other diabetes drugs, according to a study published on Friday .
The study did not specify which GLP-1 medicines the patients took, but the records were for patients on these medicines or insulin or the diabetes drug metformin between March 2005 and November 2018. Ozempic was only approved by the US Food and Drug Administration in December 2017. The authors of the study did not report having received funds from drugmakers who market these medicines.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: